Five Prime Therapeutics, Inc. to Present at Future Leaders in the Biotech Industry Conference in New York

        Print
| Source: Five Prime Therapeutics, Inc.

SOUTH SAN FRANCISCO, Calif., April 7, 2011 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc., a leader in innovative biologics, announced today that Lewis T. "Rusty" Williams, M.D., Ph.D., executive chairman and founder, and Julia P. Gregory, president and chief executive officer, will present at the Future Leaders in the Biotech Industry Conference at the Millennium Broadway Hotel & Conference Center, New York, New York. Their presentation will take place on Friday, April 15, 2011, at 10:00 a.m., Eastern Daylight Time. Ms. Gregory and Dr. Williams will present an overview of FivePrime and discuss the company's advancements in its clinical and preclinical development programs and its recent collaboration with Human Genome Sciences, Inc. for FP1039 for solid tumors.

About FivePrime

Five Prime Therapeutics, Inc. is a clinical-stage, privately held, biotechnology company discovering and developing innovative protein and antibody therapeutics. Using its novel, high-tech discovery platform, FivePrime is building a strong pipeline of oncology, immunology and metabolic disease drug candidates. Its proprietary platform mines FivePrime's comprehensive library of secreted and extracellular human proteins to screen for medically relevant new therapeutic proteins and antibody targets. FivePrime has active collaborations with Pfizer, Inc. in the fields of oncology and diabetes and GlaxoSmithKline for skeletal muscle disorders and Human Genome Sciences, Inc. for development and commercialization in the United States, Canada and the EU of FP1039 for solid tumors. For more information about FivePrime, please visit FivePrime's web site at www.fiveprime.com.

The Five Prime Therapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8029

Five Prime Therapeutics, Inc.
Two Corporate Drive
South San Francisco, CA 94080
Debbie Tobin, 415-365-5721